Login / Signup

Osteoprotegerin is an Early Marker of the Fibrotic Process and of Antifibrotic Treatment Responses in Ex Vivo Lung Fibrosis.

Kurnia S S PutriAdhyatmika AdhyatmikaCarian E BoorsmaHabibie HabibieMitchel J R RuigrokPeter HeukelsHidde J HaismaMarina H de JagerWouter L J HinrichsPeter OlingaBarbro N Melgert
Published in: Lung (2024)
OPG can already be detected during the early stages of fibrosis development and responds, both in early- and late-stage fibrosis, to treatment with antifibrotic drugs currently on the market for lung fibrosis. Therefore, OPG should be further investigated as a potential biomarker for lung fibrosis and a potential surrogate marker for treatment effect.
Keyphrases
  • liver fibrosis
  • combination therapy
  • risk assessment
  • high resolution
  • health insurance
  • idiopathic pulmonary fibrosis
  • mass spectrometry
  • replacement therapy